(Q51565136)

7 April 2018

title

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. (English)

1 reference

7 April 2018

author name string

Burcelin R

series ordinal

1

1 reference

7 April 2018

Dolci W

series ordinal

2

1 reference

7 April 2018

Thorens B

series ordinal

3

1 reference

7 April 2018

publication date

1 February 1999

1 reference

7 April 2018

published in

Metabolism

1 reference

7 April 2018

volume

48

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

252-258

1 reference

7 April 2018

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Glucagonlike peptide I (7-37) actions on endocrine pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP- 1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Peptidases II. Localization of dipeptidylpeptidase IV (DPP IV). Histochemical and biochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990043-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0026-0495(99)90043-4

1 reference

7 April 2018

1 reference

7 April 2018